Applying CE and microchip CE to molecular cancer analysis: From research to clinical utility

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000193" target="_blank" >RIV/26475821:_____/13:#0000193 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Applying CE and microchip CE to molecular cancer analysis: From research to clinical utility
Original language description
A poster demonstrating the use of CE and chip CE in analysis of various molecular cancer markers Decisions in clinical oncology are growingly relying on modern tools and technologies coming from genome research. Currently, several treatment options are available to most patients suffering from common forms of solid cancers (e.g.colorectal, lung, pancreas ...). The clinical decision is taken based on the extent of the tumor defined by TNM (tumor, nodes, metastasis) or other types of staging. The treatment options usually include surgical removal of tumorous tissue, irradiation of the tumor, pharmacological chemotherapy or a combination thereof. Assessment of the disease prognosis is often the key component in the decision process. A number of molecularaberrations found in cancerous tissue such as DNA mutations, gene amplifications or DNA hypermethylation may be utilized as biomarkers defining the disease prognosis. Such molecular markers may also be used to predict the likelihood of a
Czech name
—
Czech description
—

Project
<a href="/en/project/NT13638" target="_blank" >NT13638: The clinical significance of epigenetic factors for improvement of diagnosis, assessment of prognosis and the risk of recurrence after curative resection for pancreatic cancer.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)